Cited by 131Health Systems, Economic Evaluations, Quality of LifeTechnology and Human Factors in Education and HealthPharmaceutical Economics and Policy

The future of precision medicine: potential impacts for health technology assessment

Open access
Love-Koh, James, Peel, Alison, Rejon-Parrilla, Juan Carlos, Ennis, Kate, Lovett, Rosemary, Manca, Andrea, Chalkidou, Anastasia, Wood, Hannah +1 more·2018·PharmacoEconomics

Abstract

OBJECTIVE: Precision medicine allows healthcare interventions to be tailored to groups of patients based on their disease susceptibility, diagnostic or prognostic information, or treatment response. We analysed what developments are expected in precision medicine over the next decade and considered the implications for health technology assessment (HTA) agencies. METHODS: We performed a pragmatic literature search to account for the large size and wide scope of the precision medicine literature. We refined and enriched these results with a series of expert interviews up to 1 h in length, including representatives from HTA agencies, research councils and researchers designed to cover a wide spectrum of precision medicine applications and research. RESULTS: We identified 31 relevant papers and interviewed 13 experts. We found that three types of precision medicine are expected to emerge in clinical practice: complex algorithms, digital health applications and 'omics'-based tests. These are expected to impact upon each stage of the HTA process, from scoping and modelling through to decision-making and review. The complex and uncertain treatment pathways associated with patient stratification and fast-paced technological innovation are central to these effects. DISCUSSION: Innovation in precision medicine promises substantial benefits but will change the way in which some health services are delivered and evaluated. The shelf life of guidance may decrease, structural uncertainty may increase and new equity considerations will emerge. As biomarker discovery accelerates and artificial intelligence-based technologies emerge, refinements to the methods and processes of evidence assessments will help to adapt and maintain the objective of investing in healthcare that is value for money.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s40273-018-0686-6

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Other biomarkers such as protein expression, gut microbiome, and metabolic profile are employed with machine learning to enable personalized treatments.

    “In addition to genetic information, other biomarkers such as protein expression, gut microbiome, and metabolic profile are also employed with machine learning to enable personalized treatments [12].”
  • Omics-based tests use genetic information from a population pool with machine learning algorithms to find correlations and predict treatment responses for individual patients.

    “Omics-based tests: Genetic information from a population pool is used with machine learning algorithms to find correlations and predict treatment responses for the individual patient.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. [46]Academy of Medical Sciences Health economics for stratified medicine. Summary of a workshop held on 5 October 2016 by the Academy of Medical Sciences and the UK Pharmacogenetics and Stratified Medicine Network 2016 London Academy of Medical Sciences 2016
  2. [73]National Institute for Health and Care Excellence Fast track appraisal: addendum to the guide to the processes of technology appraisal 2017 London NICE 27905710

Cited by

Sorted by citations

Authors
Love-Koh, J., Peel, A., Rejon-Parrilla, J. C., Ennis, K., Lovett, R., Manca, A., Chalkidou, A., Wood, H., & Taylor, M.
Affiliations
  • University of York (GB)
  • University of Liverpool (GB)
  • National Institute for Health and Care Excellence (GB)
  • Luxembourg Institute of Health (LU)
Corresponding author
Love-Koh, James
Venue
PharmacoEconomics
Published
2018-07-13
Volume
36
Issue
12
Pages
1439-1451
ISSN
  • 1170-7690 (ISSN-L)
  • 1179-2027
OpenAlex
W2884983901
Cited by
131
References
53
Citations by year
2026: 8 · 2025: 11 · 2024: 17 · 2023: 25 · 2022: 16 · 2021: 28 · 2020: 15 · 2019: 11
FWCI
20.46
Type
journal article
Language
en
Open access
Locations
  • PharmacoEconomics (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Research Portal (King's College London) (submittedVersion, cc-by-nc)
Funders
National Institute for Health and Care Excellence
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Technology and Human Factors in Education and Health
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Keywords
precision medicine, health technology assessment, patient stratification, digital health applications, artificial intelligence in healthcare, structural uncertainty, health care equity, value for money, decision-making
MeSH terms
Artificial Intelligence, Decision Making, Humans, Technology Assessment, Biomedical, Biomarkers, Biomedical Technology, Uncertainty, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review